2. Application of Ascorbate in Cancer Therapy
The role of ascorbate has been studied in both animal and in vitro models, both for its cytotoxic effect as a monotherapy treatment and as an adjuvant to oncologic therapies. Ascorbate been shown to have a cytotoxic effect in a colorectal cancer cell line, where its effect is dependent on the expression of sodium-dependent vitamin C transporter 2 (SVCT-2)
[15][16][27,73]. In gastric cancer cell lines, the sensitivity of cells to the cytotoxic effect of ascorbate was inversely correlated with GLUT-1 expression, suggesting GLUT-1 expression as a biomarker predicting sensitivity to ascorbate therapy
[17][75]. Direct cytotoxic effects of ascorbate were also demonstrated in a murine model of melanoma
[18][76].
As an adjuvant to conventional chemotherapy treatments, ascorbate has been shown in non-small-cell lung cancer cell lines to enhance the cytotoxicity of chemotherapy
[19][20][77,78]. In pancreatic cancer cell lines, ascorbate enhances the cytotoxic effect of gemcitabine and paclitaxel by decreasing chemoresistance
[21][79]. In a study that included in vitro experiments with 11 different cancer cell lines, around half of the cell lines tested were resistant to ascorbate cytotoxicity, a response associated with high levels of catalase activity
[22][80], suggesting a potential role for catalase in mediating ascorbate’s cytotoxicity effects. Finally, both cell lines and a murine xenograft model of colorectal cancer with KRAS mutation demonstrated that high concentrations of ascorbate enhanced the cytotoxic effect of chemotherapy
[23][81]. In parallel, in preclinical models of KRAS-mutated colorectal cancer, the combination of ascorbate and chemotherapy improved tumour regression, and this response depended on SVCT-2 expression in tumour cells
[24][82].
More recently, ascorbate has also been powerfully combined with biological therapy in cancer treatment. In HER2-positive breast cancer cell lines, treatment with high concentrations of ascorbate and a monoclonal antibody targeting HER2, trastuzumab, resulted in a decrease in tumour cell proliferation compared to trastuzumab alone
[25][83]. Furthermore, a combination of a high concentration of ascorbate and immunotherapy (anti PD1 and/or anti CTLA4 antibodies) showed improved cytotoxic effects in pancreatic, breast, melanoma, and colorectal cancer models
[26][84]. These promising results suggest that ascorbate enhances cytotoxic tumour cell killing in immunotherapy. Further studies addressing the mechanisms of this phenomenon will make clear whether this synergy will be clinically relevant.
Overall, observational prospective cohort studies have found no association or a modest inverse association between ascorbate intake and the risk of cancer
[27][28][29][30][97,98,99,100].
In breast cancer, two large prospective studies found that dietary intake of ascorbate is inversely associated with breast cancer incidence in certain subgroups. In one study (the Nurses’ Health Study), premenopausal women with a family history of breast cancer who consumed an average of 205 mg/day of ascorbate from food had a lower risk of breast cancer than those who consumed an average of 70 mg/day
[31][101]. In a second study (referred to as the Swedish Mammography Cohort), overweight women who consumed an average of 110 mg/day of ascorbate had a lower risk of breast cancer compared with overweight women who consumed an average of 31 mg/day
[32][102]. More recent prospective cohort studies reported no association between dietary or supplemental ascorbate oral intake and breast cancer
[33][34][103,104].
Ascorbate has been used to promote damage to cancer cells in radiotherapy and chemotherapy through oxidative stress generation. Ascorbate has been shown to have cytotoxic effects as a therapy adjuvant to chemoradiation in the treatment of oesophageal cancer
[35][116] and gastric cancer
[36][117], non-small-cell lung cancer and glioblastoma
[20][78], and pancreatic cancer
[37][38][118,119]. In addition, intravenous ascorbate has been found to mitigate damage to normal tissue following chemoradiation therapy
[39][40][91,120], and it may also have synergistic effects with palliative radiotherapy in patients with bone metastases
[41][121].
The effect of ascorbate has been proven as an adjuvant therapy to chemotherapy, as well. Several studies, including case reports and clinical trials, have studied the effect of IV ascorbate in patients with different types of cancer. Two initial reports showed that high-dose IV ascorbate treatment is well tolerated in cancer patients
[42][43][122,123]. However, one study with only three cases showed long survival times of patients
[43][123], while the second study, reporting 24 cases, failed to detect any anti-cancer activity of ascorbate
[42][122]. In a study with 60 patients with different types of cancer, IV ascorbate improved quality of life
[44][124]. Ascorbate administrated alone also improved quality of life in a study including 17 patients with different solid tumours, although no patient showed an objective anti-tumour response
[45][110]. Two additional studies evaluated the effect of IV ascorbate on the survival of patients with stage IV pancreatic cancer receiving standard chemotherapy treatment. Both studies reported a reduction in tumour mass and improvements in overall survival
[46][47][111,112].